The proto-oncogene c-fos belongs to the immediate early genes (IEGs) and is rapidly and transiently expressed in brain (Herrera and Robertson, 1996). It can be induced by various stimuli and is commonly used as a marker for neuronal activation (Morgan et al., 1987; Gaiddon et al., 1996; Chowdhury et al., 2000; Gallo et al., 2018; Wakhloo et al., 2020). Like many other IEGs c-Fos is a transcription factor. It binds as heterodimer with c-Jun to AP-1 binding sites (Figure 1) and enhances the expression of many other genes involved in proliferation, differentiation, apoptosis or inflammation (Ye at al., 2014).
Animal handling: While planning a c-Fos experiment with animals you should be aware of technical pitfalls affecting your research. For instance, you should consider that c-Fos expression is time dependent, susceptible for stress and can be detected after minutes (Herrera and Robertson, 1996). It is important to take into account that many factors like animal handling itself (e.g. needle injection) or the exposure to light during the dark phase (circadian activation) can influence c-Fos expression (Asanuma and Ogawa, 1994; Herrera and Robertson, 1996). Therefore, the experiment has to be planned and conducted accurately with appropriate control groups to avoid false positive results.
IHC protocol: Another point you should care about is your immunohistochemical (IHC) protocol. It seems that the total number of c-Fos positive cells is threshold dependent. Many parameters affect the detectable number of c-Fos positive cells: tissue storage conditions, method of sectioning (cryostat or vibratome), staining parameters (e.g. incubation temperature), signal enhancing reagents (Berghorn et al., 1994; Werner et al., 1996; Mayer and Bendayan, 2001) and, above all, primary antibody selection.
c-Fos antibody: Primary antibodies differ in their specificity, sensitivity and signal to noise ratio and these properties affect the outcome of your experiment. Therefore, we aim to provide highly specific and consistent c-Fos antibodies to support scientific research and experimental reproducibility. Since monoclonal antibodies have several advantages compared to polyclonal antibodies, we developed a new monoclonal recombinant rabbit anti-c-Fos antibody.
Antibodies share a common structure consisting of two heavy chains and two light chains (Figure 2). Both heavy and light chains contain species-specific constant regions and variable sequences which are responsible for target recognition (Davies and Metzger, 1983).
Figure 2: Antibody scheme. Antibodies consist of two heavy and two light chains. Both heavy and light chains contain species-specific constant regions and variable sequences which are responsible for target recognition
Figure 2: Antibody scheme. Antibodies consist of two heavy and two light chains. Both heavy and light chains contain species-specific constant regions and variable sequences which are responsible for target recognition
In monoclonal antibody preparations originating from a defined hybridoma cell line, all individual antibody molecules are identical and share the same antigen recognition site. In contrast, polyclonal antibodies like the rabbit c-Fos antibody 226 003 consist of a mixture of antibody molecules that differ in their target recognition sequences. Once a serum is used up, a new animal has to be immunized. The obtained new serum contains a new mixture of c-Fos antibodies with new specificity and affinity properties, resulting in batch to batch variations concerning the experimental performance of the polyclonal c-Fos antibody.
With our monoclonal recombinant rabbit c-Fos antibody 226 008 we have permanently solved the problem of batch to batch variations. We sequenced the c-Fos target recognition domains of our consistently well performing rat monoclonal c-Fos antibody 226 017 and fused them to the constant antibody regions of a rabbit IgG (Figure 3).
This highly defined monoclonal recombinant antibody can be expressed in mammalian cells under controlled conditions as an infinite resource with minimal batch to batch variations. It shows superior performance in our tested standard applications and is equivalent to or even better than our best rabbit polyclonal c-Fos batches (Figure 4). While the polyclonal rabbit anti-c-Fos antibody 226 003 is very susceptible to changes in experimental conditions (for example, the incubation temperature in IHC experiments has an impact on signal intensity), the monoclonal recombinant rabbit anti-c-Fos antibody 226 008 leads to robust staining results in various experimental setups and is therefore the best choice for your experiments.
As time progresses, this monoclonal antibody will be used for many different applications and all the information gathered will contribute to a better characterization of this research reagent.
In contrast to polyclonal antibodies, this information accumulates and is never lost, making this research reagent an increasingly valuable and reliable tool in your hands.
Figure 4: The monoclonal recombinant rabbit anti-c-Fos antibody 226 008 shows an excellent performance in all our standard applications. The recombinant rabbit anti-c-Fos antibody 226 008 was compared with the monoclonal rat anti-c-Fos antibody 226 017 and with the polyclonal rabbit anti-c-Fos antibody 226 003 under the same experimental conditions. In IHC and IHC-P experiments, c-Fos antibodies were utilized for indirect immunostaining of mouse and rat hippocampus sections (mouse sections shown; IHC: c-Fos = red, DAPI = blue; IHC-P: c-Fos = brown, haematoxylin = blue). In ICC experiments, c-Fos antibodies were used for indirect immunostaining of rat hippocampus neurons (c-Fos = red, MAP 2 188 011/188 002 = green, DAPI = blue). In western blot experiments, c-Fos was detected in nuclear extracts from TPA-stimulated HeLa cells (detection: AP-staining).
New tissue-clearing techniques such as CLARITY and iDISCO allow completely new insights into biological processes and structures. In combination with our monoclonal recombinant rabbit anti-c-Fos antibody 226 008 they enable to study pathways in the brain throughout relatively large areas. It has been shown how to assess overlapping cell populations in the same mouse by marking engram cells using a modified version of CLARITY in combination with our c-Fos antibody 226 008 (Refaeli et al. 2024).
Figure 5: Indirect immunostaining of a sagittal section of a mouse brain including cortex with rabbit monoclonal anti-c-Fos (cat. no. 226 008, diluation 1:500; red) after optical clearing by iDISCO.
Courtesy: May Hui and Kevin Beier, University of California, Irvine.
Figure 5: Indirect immunostaining of a sagittal section of a mouse brain including cortex with rabbit monoclonal anti-c-Fos (cat. no. 226 008, diluation 1:500; red) after optical clearing by iDISCO.
Courtesy: May Hui and Kevin Beier, University of California, Irvine.
| Cat. No. | Product Description | Application | Quantity | Price | Cart |
|---|
| 226 008 | c-Fos, rabbit, monoclonal, recombinant IgGrecombinant IgG | WB ICC IHC IHC-P iDISCO Clarity | 50 µg | $425.00 |   |
| 226 009 | c-Fos, chicken, monoclonal, recombinant IgYrecombinant IgY | WB ICC IHC IHC-P | 50 µg | $415.00 | |
| 226 017 | c-Fos, rat, monoclonal, purified IgG IgG | WB ICC IHC IHC-P FACS | 100 µg | $425.00 | |
| 226 308 | c-Fos, Guinea pig, monoclonal, recombinant IgGrecombinant IgG | WB ICC IHC IHC-P | 50 µg | $425.00 | |
| 188 002 | MAP2, rabbit, polyclonal, antiserumantiserum | WB ICC IHC IHC-P | 200 µl | $360.00 | |
| 188 011 | MAP2, mouse, monoclonal, purified IgG IgG | WB ICC IHC IHC-P DNA-PAINT | 100 µg | $420.00 | |
Asanuma and Ogawa, 1994: Pitfalls in Assessment of c-fos mRNA Expression in the Brain: Effects of Animal Handling. PMID: 7827709
Berghorn et al., 1994: cFos Immunoreactivity Is Enhanced with Biotin Amplification. PMID: 7983364
Chowdhury et al., 2000: Induction and adaptation of Fos expression in the rat brain by two types of acute restraint stress. PMID: 10822158
Davies and Metzger, 1983: Structural basis of antibody function. PMID: 6399980
Gaiddon et al., 1996: Brain-derived neurotrophic factor stimulates AP-1 and cyclic AMP-responsive element dependent transcriptional activity in central nervous system neurons PMID: 8632149
Gallo et al., 2018: Immediate Early Genes, Memory and Psychiatric Disorders: Focus on c-Fos, Egr1 and Arc. PMID: 29755331
Glover and Harrison, 1995: Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. PMID: 7816143
Herrera and Robertson, 1996: Activation of c-fos in the brain. PMID: 8971979
Mayer and Bendayan, 2001: Amplification methods for the immunolocalization of rare molecules in cells and tissues. PMID: 11194866
Morgan et al., 1987: Mapping Patterns of c-fos Expression in the Central Nervous System After Seizure. PMID: 3037702
Refaeli et al., 2024: Analyzing engram reactivity and long-range connectivity. PMID: 38280198
Sheng and Greenberg, 1990: The Regulation and Function of c-fos and Other Immediate Early Genes in the Nervous System. PMID: 1969743
Wakhloo et al., 2020: Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin. PMID: 32152318
Werner et al. 1996, Antigen retrieval, signal amplification and intensification in immunohistochemistry. PMID: 9072182
Ye et al., 2014: Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1). PMID: 24831826
